Liquidia Corporation (LQDA )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol LQDA
- Company Liquidia Corporation
- Price $64.01
- Changes Percentage 0.17
- Change 0.11
- Day Low $61.72
- Day High $65.95
- Year High $63.46
- Year Low $11.85
- Market Cap $4,952,405,833
- Price Avg 50 EMA (D) $44.89
- Price Avg 200 EMA (D) $34.56
- Exchange NASDAQ
- Volume 1,336,848
- Average Volume 1,371,459
- Open $64.41
- Previous Close $63.9
- EPS 0.17
- PE 327.59
- Earnings Announcement 2026-08-11 04:00:00
- Shares Outstanding $88,928,099
Company brief: LIQUIDIA CORPORATION (LQDA )
- Healthcare
- Biotechnology
- Dr. Roger A. Jeffs Ph.D.
- https://www.liquidia.com
- US
- N/A
- 07-26-2018
- US53635D2027
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.